Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Cancelled)
- 2. (Currently Amended) The use method of claim 4 30 wherein the disorder is cancer.
- 3. (Currently Amended) The use of claim 1 method of claim 30 wherein the disorder is an at least partially irradiation and/or medicament-resistant cancer.
- 4. (Currently Amended) The use of claim 1 method of claim 30 wherein the disorder is at least partially resistant against apoptosis-inducing therapy.
- (Currently Amended) The use of claim 1 method of claim 30 wherein the
 disorder is at least partially resistant against administration of cytostatic and/or
 cytotoxic medicaments, particularly apoptosis-inducing medicaments.
- (Currently Amended) The use of claim 1 method of claim 30 wherein the inhibitor of a receptor tyrosine kinase ligand is co-applied with a further therapeutic procedure and/or medicament.
- (Currently Amended) The <u>use-method</u> of claim 6 wherein the medicament is co-applied with an irradiation therapy.
- (Currently Amended) The use method of claim 6 wherein the medicament is co-applied with a further anti-cancer medicament, particularly with a chemotherapeutic agent or with an anti-tumour antibody.

- 9. (Currently Amended) The use method of claim 8 wherein the further anticancer medicament is selected from doxorubicin, a taxane, cis/trans-platin or derivatives thereof, 5-fluorouracil, mitomycin D, paclitaxel, etoposide, cyclophosphoamide, docetaxel or other apoptosis-inducing drugs or proteins, in particular antibodies.
- 10. (Cancelled)
- 11. (Cancelled)
- 12. (Cancelled)
- 13. (Currently Amended) The use of claim 12 method of claim 33, wherein the stress is an oxidative and/or osmotic stress.
- 14. (Currently Amended) The use of claim 12 method of claim 33, wherein the stress is a p38-mediated stress.
- 15. (Currently Amended) The use of claim 12 method of claim 33, wherein the disorder is cancer.
- 16. (Currently Amended) The use of claim 1 method of claim 30 wherein the receptor tyrosine kinase is selected from EGFR and other members of the EGFR family.
- 17. (Currently Amended) The use of claim 1 method of claim 30, wherein the receptor is EGFR.
- 18. (Currently Amended) The method of claim 4 30 wherein the receptor tyrosine kinase ligand is a ligand binding to the extracellular domain of said receptor tyrosine kinase.

- 19. (Currently Amended) The use of claim 1 method of claim 30 wherein the receptor tyrosine kinase ligand is selected from HB-EGF, EGF, amphiregulin, betacellulin, epiregulin, TGF-α, neuregulin or heregulin.
- 20. (Currently Amended) The <u>use method</u> of claim 19 wherein the receptor tyrosine kinase ligand is HB-EGF.
- 21. (Currently Amended) The use of claim 1 method of claim 30 wherein the inhibitor is an inhibitor of a metalloprotease capable of cleaving the receptor tyrosine kinase ligand or an inhibitor of regulatory steps upstream of the metalloprotease.
- 22. (Currently Amended) The use of claim 1 method of claim 30 wherein the inhibitor is a direct inhibitor of the receptor tyrosine kinase ligand.
- 23. (Currently Amended) The use of claim 1 method of claim 30 wherein the inhibitor acts on the nucleic acid level.
- 24. (Currently Amended) The <u>use method</u> of claim 23 wherein the inhibitor is a specific transcription inhibitor, particularly selected from anti-sense molecules, ribozymes or RNAi molecules.
- 25. (Currently Amended) The <u>use method</u> of claim 24 wherein the inhibitor is a gene inactivator.
- 26. (Currently Amended) The use of claim 1 method of claim 30 wherein the inhibitor acts on the protein level.
- 27. (Currently Amended) The use method of claim 26 wherein the inhibitor is a specific protein inhibitor, particularly selected from antibodies or antibody fragments and/or from roteinaceous or low-molecular weight inhibitors.

- 28. (Original) A pharmaceutical composition or kit comprising as active ingredients
 - (a) an inhibitor of a receptor tyrosine kinase ligand which is an inhibitor of a metalloprotease capable of cleaving the receptor tyrosine kinase ligand or an inhibitor of regulatory steps upstream of the metalloprotease, and
 - (b) a further medicament for the treatment of hyperproliferative disorders.
- 29. (Original) The composition or kit of claim 28 which additionally comprises pharmaceutically acceptable carriers, diluents and/or adjuvants.
- 30. (Original) A method of preventing or treating an at least partially therapyresistant hyperproliferative disorder comprising administrating an inhbitor of a receptor tyrosine kinase ligand to a subject in need thereof.
- 31. (New) A method for increasing the efficacy of therapies against hyperproliferative disorders in a patient in need of such increase, comprising administering to the patient a therapeutically effective amount of an inhibitor of a receptor tyrosine kinase ligand.
- 32. (New) A method for increasing the sensitivity of hyperproliferative disorders against irradiation and/or medicament treatment in a patient in need of such increased sensitivity, comprising administering to said patient a therapeutically effective amount of an inhibitor of a receptor tyrosine kinase ligand.
- 33. (New) A method of preventing or treating a hyperproliferative disorder which is caused by or associated with stress-induced activation of a receptor tyrosine kinase in a patient in need of such prevention or treatment, comprising administering to said patient a therapeutically effective amount of an inhibitor of a receptor tyrosine kinase ligand.